EHP-102 is an oral pharmaceutical product candidate derived from cannabigerol (CBG), another key cannabinoid molecule. CBG has been shown to be anti-inflammatory and shows evidence of neuroprotection. The novel active molecule of EHP-102 has been modified to provide even more potent effects compared to CBG by also affecting PPARγ, a key molecular target for the treatment of Huntington’s and Parkinson’s diseases, as well as other pathways involved in the pathophysiology of neurodegenerative diseases. These characteristics have led EHP to develop this proprietary new drug candidate for Huntington’s disease and Parkinson’s disease.

In preclinical studies to date, EHP-102 has demonstrated the potential to promote the regeneration of nerve cells, protect against neuroinflammation and neurodegeneration in Huntington’s disease and reduce the loss of dopamine production in Parkinson’s disease. These data support EHP-102’s potential to be disease-modifying rather than only symptomatic, thus possibly providing a beneficial treatment option for these complex diseases with no cure.